Mereo Biopharma Group (MREO) Q3 2025 earnings summary

Executive summary

• Focused on developing therapeutics for rare diseases, with late-stage candidates setrusumab (OI) and alvelestat (AATD-LD), and vantictumab in early-stage partnered development.

• Approaching key transition with Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, with data expected by end of 2025.

• Commercial readiness activities underway in Europe for setrusumab, targeting expanded markets.

• Active partnering discussions for alvelestat and new partnership for vantictumab, retaining European rights.

• Strategy centers on acquiring and developing rare disease assets with significant prior investment and data.

Financial highlights

• Net loss for Q3 2025 was $7.0M, a significant improvement from $15.0M in Q3 2024; net loss for the nine months ended September 30, 2025 was $34.5M, down from $36.2M year-over-year.

• Revenue of $0.5M in the nine months ended September 30, 2025, from a milestone payment related to leflutrozole; no revenue in the prior year period.

• Cash and cash equivalents were $48.7M as of September 30, 2025, down from $69.8M at December 31, 2024, and expected to fund operations for at least 12 months from filing.

• Operating cash outflow for the nine months was $23.3M, nearly flat year-over-year.

• Operating loss for Q3 2025 was $10.0M.

Outlook and guidance

• Current cash resources expected to fund operations into 2027, but additional funding will be needed for full development and commercialization plans.

• Plans to seek non-dilutive funding, equity, or debt financing as needed.

• Guidance does not include potential partnership payments for alvelestat or non-core business development.

• Phase 3 data for setrusumab expected around end of 2025; pivotal Phase 3 for alvelestat in preparation.